Welcome to our dedicated page for Neurosense Therapeutics SEC filings (Ticker: NRSN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeuroSense Therapeutics Ltd. (NRSN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. NeuroSense files current reports on Form 6-K and annual reports on Form 20-F under the Securities Exchange Act of 1934, detailing clinical, regulatory, corporate and financing developments related to its neurodegenerative disease programs.
In these filings, NeuroSense reports key milestones for its lead drug candidate PrimeC, a novel extended-release oral formulation that combines ciprofloxacin and celecoxib in a fixed dose. Recent 6-K reports have furnished press releases on topics such as FDA clearance to initiate a pivotal Phase 3 trial of PrimeC in ALS, database lock for the RoAD Phase 2 Alzheimer’s disease study, and biomarker findings indicating statistically significant reductions in Alzheimer’s disease–associated microRNAs.
Other 6-K submissions include notices and proxy statements for shareholder meetings, descriptions of private placement transactions in ordinary shares, and business updates that summarize clinical trial data, regulatory interactions with agencies like the FDA and Health Canada, and manufacturing scale-up activities. Certain 6-K reports state that they are incorporated by reference into NeuroSense’s registration statements on Form F-3 and Form S-8, which relate to securities offerings and equity compensation plans.
On Stock Titan, these filings are updated as they are released through EDGAR. AI-powered tools can help readers quickly understand the focus of each 6-K or 20-F by summarizing clinical trial disclosures, regulatory announcements, financing terms and shareholder matters. This allows investors and researchers to review NeuroSense’s official statements on the development of PrimeC in ALS and Alzheimer’s disease, corporate governance actions and capital-raising activities without reading every document in full.
NeuroSense Therapeutics Ltd. filed a Form F-3 to register 333,334 ordinary shares for resale by the selling shareholder. These shares were issued in a September 2025 private placement under a purchase agreement. We will not receive any proceeds from sales by the selling shareholder; they bear the sale decisions and receive all proceeds.
As context, the company had 29,550,970 ordinary shares outstanding as of October 27, 2025. The September 2025 private placement priced shares at $1.50 for gross proceeds of approximately $0.5 million. NeuroSense’s ordinary shares and warrants trade on Nasdaq as NRSN and NRSNW; on October 27, 2025, NRSN closed at $1.14. The prospectus permits various sale methods by the selling shareholder and does not obligate any sale.
NeuroSense Therapeutics Ltd. filed a Form 6-K to share new clinical information about its drug candidate PrimeC. The company reports, via an attached press release dated October 6, 2025, that PrimeC produces statistically significant reductions in Alzheimer’s disease biomarkers, which are biological signals linked to Alzheimer’s disease activity. The press release describing these results is furnished as Exhibit 99.1 to this report.
NeuroSense Therapeutics Ltd. reports that it held its Annual General Meeting of Shareholders on September 25, 2025. All resolutions presented at the meeting, as described in the company’s earlier Notice and Proxy Statement furnished on Form 6-K on August 21, 2025, were approved by shareholders. The company also states that this Form 6-K is incorporated by reference into its existing registration statements on Form S-8 and Form F-3, meaning the information in this report becomes part of those securities registration documents.
NeuroSense Therapeutics Ltd. filed a Form 6-K after issuing a press release on its Alzheimer’s program. The company reported that its drug candidate shows early signals of benefit in neurons derived from Alzheimer’s patients, suggesting a potentially encouraging effect at the cellular level, though still at an early research stage.
The company is also using this report to update its existing shelf and equity compensation registration statements. The Form 6-K, including only part of Exhibit 99.1 as specified, is incorporated by reference into NeuroSense’s Form S-8 and multiple Form F-3 registration statements, meaning those SEC documents now formally include the information contained in this submission.
NeuroSense Therapeutics Ltd. reports limited clinical survival outcomes and filing cross-references. In the sample presented, 50% (15 of 30) of participants originally randomized to the investigational treatment PrimeC remain alive, while approximately 7% (1 of 14) of participants originally randomized to placebo remain alive. The report also incorporates references to Form S-8 (File No. 333-262480) and multiple Form F-3 filings (File Nos. 333-269306, 333-260338, 333-283656 and 333-284051) to be part of the report from the submission date, subject to any later superseding documents. The filing is signed by CEO Alon Ben-Noon.
NeuroSense Therapeutics Ltd. submitted a Form 6‑K reporting that certain registration statements (Form S‑8 and multiple Form F‑3 filings) are incorporated by reference. The report attaches a Form of Securities Purchase Agreement dated September 4, 2025 between NeuroSense and the purchaser named on the signature pages, and a Press Release dated September 4, 2025. The filing is signed by Alon Ben‑Noon, Chief Executive Officer.
NeuroSense reported a statistically significant clinical benefit for PrimeC at 18 months. An NfL-adjusted MMRM analysis showed a p=0.03 result, corresponding to a 28% relative difference in decline on the ALS Functional Rating Scale-Revised (ALSFRS-R) favoring patients who received PrimeC from study start versus those who began with placebo and switched to PrimeC after six months. The company states these data underscore the clinical importance of initiating PrimeC early in disease progression.
NeuroSense Therapeutics Ltd. furnished a Form 6-K to provide materials for its upcoming Annual General Meeting of Shareholders scheduled for September 25, 2025. The filing attaches and incorporates a Notice and Proxy Statement for the meeting, along with a proxy card that shareholders can use to vote on the matters presented.
The company also states that this Form 6-K is incorporated by reference into several of its existing registration statements on Form S-8 and Form F-3, meaning the information in this report is now formally part of those securities offering documents.
NeuroSense Therapeutics Ltd. reports long-term follow-up data from its Phase 2a study in people with ALS treated with its drug candidate PrimeC. As of August 20, 2025, approximately 20% of people with ALS from this study, including those continuing treatment under compassionate use, remain on PrimeC for more than 5.5 years and have lived with ALS for over 7 years. Across these multi-year treatment exposures, PrimeC is described as well tolerated, with no new safety signals observed to date. The company also notes that this report is incorporated by reference into several of its existing registration statements.
NeuroSense Therapeutics Ltd. (NRSN) filed an S-8 registering securities for an employee benefit plan and incorporated prior public filings and its Form 8-A description. The filing outlines the companys indemnification and insurance framework for officers and directors, specifying circumstances where indemnity and insurance are permitted and where they are excluded, and includes undertakings to update the registration statement with required prospectus information, material changes to distribution plans, and to remove unsold securities at offering termination.